<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="336079">
  <stage>Registered</stage>
  <submitdate>12/10/2010</submitdate>
  <approvaldate>18/11/2010</approvaldate>
  <actrnumber>ACTRN12610001007022</actrnumber>
  <trial_identification>
    <studytitle>Hemolysis, elevated liver functions and low platelets (HELLP syndrome):  Does the use of dexamethasone in the postpartum period improve maternal outcome?</studytitle>
    <scientifictitle>Hemolysis, elevated liver functions and low platelets (HELLP syndrome):  Does the use of dexamethasone in the postpartum period improve maternal hospital stay and complications?</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>nil</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>HELLP syndrome</healthcondition>
    <conditioncode>
      <conditioncode1>Reproductive Health and Childbirth</conditioncode1>
      <conditioncode2>Fetal medicine and complications of pregnancy</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Patients with HELLP syndrome was randomised to receive either dexamethasone or no dexamethasone in postpartum peroid.  the dose of dexamethasone was 24 mg on day 1, 16mg on day2 and 12 mg on day 3 and it was given intravenously.</interventions>
    <comparator>Routine postpartum care, including Magnesium sulphate and antihypertensive therapy</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Days in hospital</outcome>
      <timepoint>till discharge from hospital</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Days till platelet count more than 100 000/mm3</outcome>
      <timepoint>till discharge from hospital</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Intensive care admissions</outcome>
      <timepoint>Till discharge from hospital</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Neonatal morbidity and mortality</outcome>
      <timepoint>till discharge from hospital</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>HELLP syndrome according to Tennessee criteria
Haptoglobin in all cases to confirm hemolysis</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Partial hemolysis, elevated liver functions and low platelet (HELLP) syndrome
Thrombotic thrombocytopenic purpura (TTP)
Ideopatic thrombocytopenic purpura (ITP)
Hemolytic uremic syndrome (HUS)
Acute fatty liver of pregnancy
Cholestasis of pregnancy</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>After diagnosis of HELLP syndrome, patients were randomised to either receive dexametasone or no dexamethasone in postpartum peroid.
Randomisation was done by consecutively number opaque sealed envelopes</concealment>
    <sequence>Randomisation was done according to randomisation list provided by the department of Biostatistics, University of Free State, Bloemfontein, South Africa</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3 / Phase 4</phase>
    <anticipatedstartdate>1/10/2008</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>66</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>South Africa</country>
      <state />
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Universitas Hospital</primarysponsorname>
    <primarysponsoraddress>20 Paul Kruger Avenue 
Bloemfontein
9300</primarysponsoraddress>
    <primarysponsorcountry>South Africa</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Hospital</fundingtype>
      <fundingname>Universitas Hospital</fundingname>
      <fundingaddress>20 Paul Kruger Avenue
Bloemfontein
9300</fundingaddress>
      <fundingcountry>South Africa</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>To establish if the use of corticosteroids improve the outcome of patients with HELLP syndrome</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Ethics Review Board, University of Free State</ethicname>
      <ethicaddress>University of Free State
20 Paul Kruger Avenue
Bloemfontein
9300</ethicaddress>
      <ethicapprovaldate />
      <hrec>ETOVS 30/07</hrec>
      <ethicsubmitdate />
      <ethiccountry>South Africa</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Jacobus du Plessis</name>
      <address>Royal Womens Hospital
20 Flemington Road
Parkville
Victoria
3052</address>
      <phone>+61 3 8345 2000</phone>
      <fax />
      <email>Jacobus.DuPlessis@thewomens.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Jacobus du Plessis</name>
      <address>Royal Womens Hospital
20 Flemington Road
Parkville
Victoria
3052</address>
      <phone>+ 61 3 8345 2000</phone>
      <fax />
      <email>Jacobus.DuPlessis@thewomens.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>